Harnessing the body's tumor-killing cells with first-in-class immunotherapeutics
Recourse Biologics is committed to advancing precision therapeutics for oncology. Our lead molecule is RB101. RB101 is a first-in-class immunotherapeutic that increases professional killer cell persistence, memory formation, and cytotoxicity without systemic toxicity or exhaustion. RB101 is 12 months from IND.
In addition to RB101, Recourse Biologics has created a pipeline of compelling, first-in-class candidates. This includes validated ADCs directed at novel tumor-selective targets, and an improved method of targeting and redirecting cytotoxic lymphocytes within the tumor microenvironment using our bispecific antibody platform.
Stay updated with our latest developments, conferences, and milestones
Company will attend conference in Boston to discuss oncology approaches and preclinical assets targeting diverse tumor indications.
Read on LinkedInCompany will attend conference to discuss innovative oncology response approaches.
Read on LinkedInLead compound RB101 continues to show promising results in preclinical studies, maintaining 12-month timeline to IND filing.
Read on LinkedIn